|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
EP2314629B2
(en)
|
2002-07-18 |
2022-11-16 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
ES2378407T3
(es)
|
2006-09-01 |
2012-04-12 |
Therapeutic Human Polyclonals, Inc. |
Aumento de la expresión de inmunoglobulina humana o humanizada en animales transgénicos no humanos
|
|
RU2731084C2
(ru)
*
|
2008-06-27 |
2020-08-28 |
Мерюс Н.В. |
Продуцирующие антитела млекопитающие, не являющиеся человеком
|
|
CA2747534C
(en)
|
2008-12-18 |
2020-08-18 |
Erasmus University Medical Center Rotterdam |
Non-human transgenic animals expressing humanised antibodies and use therof
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
CN102638971B
(zh)
|
2009-07-08 |
2015-10-07 |
科马布有限公司 |
动物模型及治疗分子
|
|
US20130185821A1
(en)
*
|
2010-02-08 |
2013-07-18 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
HRP20151188T4
(hr)
*
|
2010-02-08 |
2021-10-01 |
Regeneron Pharmaceuticals, Inc. |
Miš sa zajedničkim lakim lancem
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
SI2480675T1
(sl)
*
|
2010-06-22 |
2016-08-31 |
Regeneron Pharmaceuticals, Inc. |
Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo
|
|
KR102306967B1
(ko)
|
2010-08-02 |
2021-10-01 |
리제너론 파아마슈티컬스, 인크. |
Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
|
|
CN105950654B
(zh)
*
|
2010-11-27 |
2020-03-20 |
朱坚 |
一种人源化的转基因动物
|
|
LT2738259T
(lt)
|
2011-02-25 |
2020-03-10 |
Regeneron Pharmaceuticals, Inc. |
Adam6 pelės
|
|
EP2681239B8
(en)
|
2011-02-28 |
2015-09-09 |
F. Hoffmann-La Roche AG |
Antigen binding proteins
|
|
AR085403A1
(es)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos
|
|
PT3865581T
(pt)
*
|
2011-08-05 |
2024-10-04 |
Regeneron Pharma |
Murganhos da cadeia leve universal humanizada
|
|
AU2012311286B2
(en)
|
2011-09-19 |
2018-07-26 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
EP3741862A1
(en)
|
2011-09-19 |
2020-11-25 |
Kymab Limited |
Animals, repertoires & methods for the production of human antibodies
|
|
GB2495083A
(en)
*
|
2011-09-26 |
2013-04-03 |
Kymab Ltd |
Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
PT2760471T
(pt)
*
|
2011-09-30 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Péptidos terapêuticos
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
KR20140082824A
(ko)
|
2011-10-17 |
2014-07-02 |
리제너론 파아마슈티컬스, 인크. |
제한된 면역글로불린 중쇄 마우스
|
|
WO2013063391A2
(en)
|
2011-10-28 |
2013-05-02 |
Trianni, Inc. |
Transgenic animals and methods of use
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
PT3527070T
(pt)
|
2011-12-20 |
2025-12-19 |
Regeneron Pharma |
Murganhos de cadeia leve humanizada
|
|
NZ714516A
(en)
|
2012-03-02 |
2017-06-30 |
Regeneron Pharma |
Human antibodies to clostridium difficile toxins
|
|
MX353278B
(es)
*
|
2012-03-06 |
2018-01-05 |
Regeneron Pharma |
Raton con cadena ligera comun.
|
|
DK2825036T3
(en)
*
|
2012-03-16 |
2018-07-16 |
Regeneron Pharma |
Histidine engineered light chain antibodies and genetically modified rodents to generate them
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
HK1200271A1
(en)
*
|
2012-03-16 |
2015-08-07 |
瑞泽恩制药公司 |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
AU2015227453B2
(en)
*
|
2012-03-16 |
2017-05-25 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
KR102213535B1
(ko)
*
|
2012-03-16 |
2021-02-08 |
리제너론 파마슈티칼스 인코포레이티드 |
pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
DK2838918T3
(da)
|
2012-04-20 |
2019-08-12 |
Merus Nv |
Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
|
|
KR102023401B1
(ko)
*
|
2012-05-10 |
2019-11-04 |
바이오아트라, 엘엘씨 |
다중-특이적 모노클로날 항체
|
|
KR20150023535A
(ko)
*
|
2012-06-05 |
2015-03-05 |
리제너론 파마슈티칼스 인코포레이티드 |
공통 경쇄를 사용하여 완전한 인간 이중 특이적 항체를 만드는 방법
|
|
EP3912464A1
(en)
|
2012-06-12 |
2021-11-24 |
Regeneron Pharmaceuticals, Inc. |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
PL2900694T3
(pl)
|
2012-09-27 |
2018-12-31 |
Merus N.V. |
Dwuswoiste przeciwciała igg jako aktywatory komórek t
|
|
CA2898100C
(en)
|
2013-01-14 |
2023-10-10 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
MY185881A
(en)
|
2013-02-20 |
2021-06-14 |
Regeneron Pharma |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
CA2900832A1
(en)
*
|
2013-02-20 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized t-cell co-receptors
|
|
CA2900824A1
(en)
*
|
2013-02-22 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized major histocompatibility complex
|
|
CA3249218A1
(en)
*
|
2013-03-11 |
2026-03-02 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
|
|
EP4218409B1
(en)
*
|
2013-03-13 |
2025-02-12 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
JP2016519568A
(ja)
*
|
2013-03-13 |
2016-07-07 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
共通軽鎖のマウス
|
|
PL2967012T3
(pl)
|
2013-03-14 |
2021-04-19 |
Erasmus University Medical Center Rotterdam |
Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
|
SG10201800492PA
(en)
|
2013-04-29 |
2018-03-28 |
Hoffmann La Roche |
Human fcrn-binding modified antibodies and methods of use
|
|
US20150033372A1
(en)
*
|
2013-05-01 |
2015-01-29 |
Kymab Limited |
Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
JP6621750B2
(ja)
|
2013-09-18 |
2019-12-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ヒスチジン操作軽鎖抗体およびそれを生成するための遺伝子改変非ヒト動物
|
|
BR112016006502A2
(pt)
|
2013-09-30 |
2017-09-19 |
Chugai Pharmaceutical Co Ltd |
Método para a produção de molécula de ligação de antígeno usando-se fago auxiliar modificado
|
|
CA2925723A1
(en)
|
2013-10-01 |
2015-04-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
RU2016115866A
(ru)
|
2013-10-11 |
2017-11-16 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
|
|
BR112016014969A2
(pt)
|
2014-01-15 |
2018-01-23 |
Hoffmann La Roche |
polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
|
|
EP3835318B1
(en)
|
2014-01-15 |
2025-10-29 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
*
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
SMT202500020T1
(it)
|
2014-02-28 |
2025-03-12 |
Merus Nv |
Anticorpo che lega erbb-2 ed erbb-3
|
|
EP3786186A1
(en)
|
2014-02-28 |
2021-03-03 |
Merus N.V. |
Antibodies that bind egfr and erbb3
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
CN106164092A
(zh)
|
2014-03-21 |
2016-11-23 |
瑞泽恩制药公司 |
表现不同结合特征的vl抗原结合蛋白
|
|
CN106255410B
(zh)
|
2014-03-21 |
2020-01-10 |
瑞泽恩制药公司 |
产生单结构域结合蛋白的非人动物
|
|
MY186389A
(en)
|
2014-05-13 |
2021-07-22 |
Univ Pennsylvania |
Compositions comprising aav expressing dual antibody constructs and uses thereof
|
|
AU2015271709B2
(en)
|
2014-06-06 |
2020-11-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
KR20170083534A
(ko)
|
2014-09-19 |
2017-07-18 |
리제너론 파마슈티칼스 인코포레이티드 |
키메라 항원 수용체
|
|
SG10201902924RA
(en)
|
2014-10-03 |
2019-05-30 |
Massachusetts Inst Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
|
WO2016071377A1
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
ES2809455T3
(es)
|
2014-11-17 |
2021-03-04 |
Regeneron Pharma |
Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
|
|
TWI711630B
(zh)
|
2014-11-21 |
2020-12-01 |
美商必治妥美雅史谷比公司 |
抗ｃｄ７３抗體及其用途
|
|
JP2017536830A
(ja)
|
2014-11-26 |
2017-12-14 |
ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． |
Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
SG11201704283PA
(en)
|
2014-11-26 |
2017-06-29 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
TWI702229B
(zh)
|
2014-12-19 |
2020-08-21 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
|
CN107278206B
(zh)
|
2014-12-19 |
2021-04-02 |
雷根尼桑斯公司 |
结合人c6的抗体及其用途
|
|
MY187045A
(en)
|
2014-12-23 |
2021-08-27 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
|
US11111314B2
(en)
|
2015-03-19 |
2021-09-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
EA035412B1
(ru)
|
2015-05-29 |
2020-06-10 |
Бристол-Майерс Сквибб Компани |
Антитела к ox40 и их применение
|
|
US10479838B2
(en)
|
2015-06-29 |
2019-11-19 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
|
MY189159A
(en)
|
2015-07-06 |
2022-01-29 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
AU2016293942B2
(en)
|
2015-07-10 |
2022-06-16 |
Merus B.V. |
Human CD3 binding antibody
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
KR102777500B1
(ko)
|
2015-09-23 |
2025-03-11 |
리제너론 파아마슈티컬스, 인크. |
최적화된 항-cd3 이중특이적 항체 및 이의 용도
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
TW202417497A
(zh)
|
2015-10-12 |
2024-05-01 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
WO2017069628A2
(en)
|
2015-10-23 |
2017-04-27 |
Merus N.V. |
Binding molecules that inhibit cancer growth
|
|
CA3005855A1
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
HUE063377T2
(hu)
|
2015-12-22 |
2024-01-28 |
Regeneron Pharma |
Anti-PD-1 antitestek és bispecifikus anti-CD20/anti-CD3 antitestek kombinációja a rák kezelésére
|
|
IL302725A
(en)
|
2016-01-13 |
2023-07-01 |
Regeneron Pharma |
Rodents having an engineered heavy chain diversity region
|
|
KR20180114223A
(ko)
|
2016-03-04 |
2018-10-17 |
더 락커펠러 유니버시티 |
증진된 효능제 활성을 갖는 cd40에 대한 항체
|
|
CA3016187A1
(en)
|
2016-03-04 |
2017-09-08 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
US10968279B2
(en)
|
2016-05-09 |
2021-04-06 |
Bristol-Myers Squibb Company |
TL1A antibodies and uses thereof
|
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
|
|
US20170332610A1
(en)
|
2016-05-20 |
2017-11-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for breaking immunological tolerance using multiple guide rnas
|
|
KR102483193B1
(ko)
|
2016-06-03 |
2023-01-04 |
리제너론 파마슈티칼스 인코포레이티드 |
외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
|
|
WO2017218515A1
(en)
|
2016-06-14 |
2017-12-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-c5 antibodies and uses thereof
|
|
CN109641049B
(zh)
*
|
2016-06-21 |
2023-07-07 |
特尼奥生物股份有限公司 |
Cd3结合抗体
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
SG11201900026TA
(en)
|
2016-07-14 |
2019-01-30 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
|
ES2975750T3
(es)
|
2016-08-26 |
2024-07-12 |
Sanofi Sa |
Anticuerpos multiespecíficos que facilitan el emparejamiento selectivo de las cadenas ligeras
|
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
|
MY200988A
(en)
*
|
2016-09-14 |
2024-01-27 |
Teneobio Inc |
CD3 Binding Antibodies
|
|
MA46417A
(fr)
|
2016-09-23 |
2019-07-31 |
Regeneron Pharma |
Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations
|
|
US10738130B2
(en)
|
2016-09-23 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
|
|
CA3040189A1
(en)
|
2016-10-13 |
2018-04-19 |
Massachusetts Institute Of Technology |
Antibodies that bind zika virus envelope protein and uses thereof
|
|
KR102745676B1
(ko)
|
2016-12-21 |
2024-12-24 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
CN110650974B
(zh)
|
2017-02-10 |
2024-04-19 |
瑞泽恩制药公司 |
用于免疫-pet成像的放射性标记的抗-lag3抗体
|
|
EA201991720A1
(ru)
|
2017-02-17 |
2020-01-20 |
Бристол-Маерс Сквибб Компани |
Антитела к альфа-синуклеину и их применения
|
|
CN110382529B
(zh)
|
2017-03-02 |
2024-03-08 |
诺华股份有限公司 |
工程化的异源二聚体蛋白质
|
|
US11780925B2
(en)
|
2017-03-31 |
2023-10-10 |
Merus N.V. |
ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
US12195551B2
(en)
|
2017-05-17 |
2025-01-14 |
Merus N.V. |
Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
|
|
ES3065816T3
(en)
|
2017-06-07 |
2026-05-08 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
WO2018237006A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
IL312322B2
(en)
|
2017-06-20 |
2026-05-01 |
Teneobio Inc |
Antibodies against BCMA containing only heavy chains
|
|
GB201710984D0
(en)
*
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
|
TW202348250A
(zh)
|
2017-07-24 |
2023-12-16 |
美商再生元醫藥公司 |
穩定化之抗體組合物及其製法
|
|
SI3665198T1
(sl)
|
2017-08-09 |
2025-06-30 |
Merus N.V. |
Protitelesa, ki vežejo egfr in cmet
|
|
BR112020004977A2
(pt)
|
2017-09-29 |
2020-10-06 |
Regeneron Pharmaceuticals, Inc. |
moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
MX2020006113A
(es)
|
2017-12-13 |
2020-08-24 |
Regeneron Pharma |
Combinaciones de anticuerpos anti-c5 y usos de las mismas.
|
|
WO2019126756A1
(en)
|
2017-12-22 |
2019-06-27 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd22
|
|
JP7358361B2
(ja)
|
2018-01-12 |
2023-10-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｉｍ３に対する抗体およびその使用
|
|
SG11202006379UA
(en)
|
2018-01-26 |
2020-07-29 |
Regeneron Pharma |
Human antibodies to influenza hemagglutinin
|
|
CA3093407A1
(en)
|
2018-03-23 |
2019-09-26 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
SG11202008799PA
(en)
|
2018-03-24 |
2020-10-29 |
Regeneron Pharma |
Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
|
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
LT3773713T
(lt)
|
2018-04-06 |
2025-08-25 |
Regeneron Pharmaceuticals, Inc. |
Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija
|
|
CN112074538B
(zh)
|
2018-04-30 |
2024-10-18 |
瑞泽恩制药公司 |
结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途
|
|
BR112020023145A2
(pt)
|
2018-05-17 |
2021-02-02 |
Regeneron Pharmaceuticals, Inc. |
anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
|
|
IL318469A
(en)
|
2018-06-14 |
2025-03-01 |
Regeneron Pharma |
Non-human animals capable of reorganizing transgenic DH-DH, and their uses
|
|
CN112513081A
(zh)
|
2018-06-14 |
2021-03-16 |
生物蛋白有限公司 |
多重特异性抗体构建体
|
|
CN112351820B
(zh)
|
2018-06-21 |
2024-10-11 |
瑞泽恩制药公司 |
双特异性抗psma x抗cd28抗体及其用途
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
KR20210049863A
(ko)
|
2018-08-23 |
2021-05-06 |
리제너론 파아마슈티컬스, 인크. |
항-Fc 엡실론-R1 알파 (FCERIA) 항체, FCERIA 및 CD3에 결합하는 이중특이적 항원-결합 분자 및 이들의 용도
|
|
PT3844189T
(pt)
|
2018-08-31 |
2025-01-29 |
Regeneron Pharma |
Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20
|
|
JP7439076B2
(ja)
|
2018-10-23 |
2024-02-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｎｐｒ１抗体およびその使用
|
|
BR112021009111A2
(pt)
|
2018-11-16 |
2021-08-24 |
Bristol-Myers Squibb Company |
Anticorpos anti-nkg2a e usos dos mesmos
|
|
US20220332800A1
(en)
|
2018-11-20 |
2022-10-20 |
Takeda Vaccines, Inc. |
Novel anti-zika virus antibodies and uses thereof
|
|
MX2021005863A
(es)
|
2018-11-21 |
2021-07-16 |
Regeneron Pharma |
Anticuerpos antiestafilococo y usos de estos.
|
|
BR112021010457A2
(pt)
|
2018-12-19 |
2021-08-24 |
Regeneron Pharmaceuticals, Inc. |
Anticorpos biespecíficos anti-muc16 x anti cd28 e usos dos mesmos
|
|
AU2019405747A1
(en)
|
2018-12-19 |
2021-06-17 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-CD28 x anti-CD22 antibodies and uses thereof
|
|
WO2020132557A1
(en)
|
2018-12-21 |
2020-06-25 |
Compass Therapeutics Llc |
Transgenic mouse expressing common human light chain
|
|
EP3914622A1
(en)
|
2019-01-22 |
2021-12-01 |
Bristol-Myers Squibb Company |
Antibodies against il-7r alpha subunit and uses thereof
|
|
MA54945A
(fr)
|
2019-02-12 |
2021-12-22 |
Regeneron Pharma |
Compositions et procédés d'utilisation d'anticorps bispécifiques pour lier un complément et un antigène cible
|
|
CA3125380A1
(en)
|
2019-02-18 |
2020-08-27 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Genetically modified non-human animals with humanized immunoglobulin locus
|
|
SG11202107589PA
(en)
|
2019-02-22 |
2021-08-30 |
Regeneron Pharma |
Rodents having genetically modified sodium channels and methods of use thereof
|
|
SG11202110341WA
(en)
|
2019-03-22 |
2021-10-28 |
Regeneron Pharma |
EGFR x CD28 MULTISPECIFIC ANTIBODIES
|
|
CR20210500A
(es)
|
2019-04-05 |
2021-11-05 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma
|
|
SG11202111258TA
(en)
|
2019-06-05 |
2021-11-29 |
Regeneron Pharma |
Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
|
|
BR112021023335A2
(pt)
|
2019-06-11 |
2022-01-04 |
Regeneron Pharma |
Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística
|
|
JP7665538B2
(ja)
|
2019-06-14 |
2025-04-21 |
テネオバイオ， インコーポレイテッド |
Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
|
|
IL288916B2
(en)
|
2019-06-21 |
2026-03-01 |
Regeneron Pharma |
Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
|
|
MA56515A
(fr)
|
2019-06-21 |
2022-04-27 |
Regeneron Pharma |
Utilisation de molécules de liaison à l'antigène bispécifiques se liant à psma et cd3 en combinaison avec une co-stimulation de 4-1bb
|
|
JP7682853B2
(ja)
|
2019-08-08 |
2025-05-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
新規抗原結合分子フォーマット
|
|
EP4013797A1
(en)
|
2019-08-15 |
2022-06-22 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules for cell targeting and uses thereof
|
|
GB201912008D0
(en)
|
2019-08-21 |
2019-10-02 |
Cambridge Entpr Ltd |
Antibody
|
|
MY207220A
(en)
|
2019-10-28 |
2025-02-06 |
Regeneron Pharma |
Anti-hemagglutinin antibodies and methods of use thereof
|
|
IL293330A
(en)
|
2019-12-02 |
2022-07-01 |
Regeneron Pharma |
mhc ii peptide protein structures and uses thereof
|
|
CN114929343B
(zh)
|
2019-12-06 |
2025-03-18 |
瑞泽恩制药公司 |
用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
JP2023519100A
(ja)
|
2020-02-11 |
2023-05-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ａｃｖｒ１抗体およびその使用
|
|
IL297601A
(en)
|
2020-04-29 |
2022-12-01 |
Teneobio Inc |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
MX2022014090A
(es)
|
2020-05-12 |
2023-02-27 |
Regeneron Pharma |
Anticuerpos antagonistas anti-glp1r y metodos de uso de los mismos.
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
KR20230018439A
(ko)
|
2020-06-02 |
2023-02-07 |
바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 |
공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
|
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
KR20230066386A
(ko)
|
2020-09-11 |
2023-05-15 |
리제너론 파마슈티칼스 인코포레이티드 |
항원 특이적 항체의 확인 및 제조
|
|
EP4214234A1
(en)
|
2020-09-18 |
2023-07-26 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof
|
|
CA3190569A1
(en)
|
2020-10-22 |
2022-04-28 |
Christopher Daly |
Anti-fgfr2 antibodies and methods of use thereof
|
|
CN118878694A
(zh)
|
2020-11-23 |
2024-11-01 |
康诺亚生物医药科技（成都）有限公司 |
一种双特异性抗体及其用途
|
|
AU2021400584A1
(en)
|
2020-12-16 |
2023-06-29 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized fc alpha receptors
|
|
JP2024503784A
(ja)
|
2020-12-18 |
2024-01-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｎｐｒ１アゴニストに結合する免疫グロブリンタンパク質
|
|
KR20230124594A
(ko)
|
2020-12-23 |
2023-08-25 |
리제너론 파마슈티칼스 인코포레이티드 |
막관통 단백질 및 이를 생산하는 세포에 결합하는 항체를 수득하는 방법
|
|
US20240317849A1
(en)
|
2020-12-23 |
2024-09-26 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses thereof
|
|
RS66868B1
(sr)
|
2021-01-28 |
2025-06-30 |
Regeneron Pharma |
Kompozicije i postupci za lečenje sindroma oslobađanja citokina
|
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
|
US12376573B2
(en)
|
2021-03-31 |
2025-08-05 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire
|
|
IL313265A
(en)
|
2021-12-06 |
2024-08-01 |
Regeneron Pharma |
Antagonistic antibodies against NPR1 and methods of using them
|
|
CA3252619A1
(en)
|
2022-02-23 |
2023-08-31 |
Xencor, Inc. |
Anti-CD28 and anti-PSMA antibodies
|
|
TW202400228A
(zh)
|
2022-02-25 |
2024-01-01 |
美商再生元醫藥公司 |
減輕細胞激素釋放症候群的給藥方案
|
|
US20250332291A1
(en)
*
|
2022-03-22 |
2025-10-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Monoclonal antibodies for targeting the cardiac conduction system
|
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
|
CA3247475A1
(en)
|
2022-04-11 |
2023-10-19 |
Regeneron Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS
|
|
CN119546644A
(zh)
|
2022-05-18 |
2025-02-28 |
瑞泽恩制药公司 |
结合cd38和4-1bb的多特异性抗原结合分子及其用途
|
|
WO2024015816A1
(en)
|
2022-07-12 |
2024-01-18 |
Regeneron Pharmaceuticals, Inc. |
Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
|
|
US20240150474A1
(en)
|
2022-10-27 |
2024-05-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvri antibodies and their use in the treatment of trauma-induced heterotopic ossification
|
|
GB202217978D0
(en)
*
|
2022-11-30 |
2023-01-11 |
Petmedix Ltd |
Rodents expressing a common light chain
|
|
TW202430641A
(zh)
|
2023-01-18 |
2024-08-01 |
美商基利科學股份有限公司 |
人類免疫球蛋白二元輕鏈轉殖基因構築體及其用途
|
|
WO2024163477A1
(en)
|
2023-01-31 |
2024-08-08 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
KR20250150011A
(ko)
|
2023-02-13 |
2025-10-17 |
리제너론 파마슈티칼스 인코포레이티드 |
항-인간 cacng1 항체를 이용한 근육 관련 장애 치료
|
|
JP2026506095A
(ja)
|
2023-02-17 |
2026-02-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞
|
|
CN121039163A
(zh)
|
2023-05-02 |
2025-11-28 |
瑞泽恩制药公司 |
抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途
|
|
CN121548588A
(zh)
|
2023-06-16 |
2026-02-17 |
里珍纳龙药品有限公司 |
Cd40 x cd40双特异性抗原结合分子及其用途
|
|
TW202519547A
(zh)
|
2023-07-10 |
2025-05-16 |
美商再生元醫藥公司 |
雙特異性PD-L1x4-1BB抗體及其使用方法
|
|
IL325400A
(en)
|
2023-07-10 |
2026-02-01 |
Regeneron Pharma |
Anti-human CACNG1 antibody-drug conjugates and their uses
|
|
KR20260036572A
(ko)
|
2023-07-10 |
2026-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
이중 특이성 PD-L1xCD28 항체 및 이의 이용 방법
|
|
WO2025042428A1
(en)
|
2023-08-18 |
2025-02-27 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025064738A1
(en)
|
2023-09-22 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Dntt 250-258 off-target peptides and uses thereof
|
|
WO2025064761A1
(en)
|
2023-09-22 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Kras10-18 g12d off-target peptides and uses thereof
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250361320A1
(en)
|
2024-02-27 |
2025-11-27 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
US20250277048A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
US20250297006A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers
|
|
US20260000758A1
(en)
|
2024-06-28 |
2026-01-01 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
|
|
WO2026006734A1
(en)
|
2024-06-28 |
2026-01-02 |
Regeneron Pharmaceuticals, Inc. |
Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
|
|
WO2026006724A1
(en)
|
2024-06-28 |
2026-01-02 |
Regeneron Pharmaceuticals, Inc. |
Prame off-target peptides and uses thereof
|
|
WO2026015729A1
(en)
|
2024-07-11 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
Gprc5d x cd28 bispecific antibodies and methods of use thereof
|
|
US20260022395A1
(en)
|
2024-07-16 |
2026-01-22 |
Gilead Sciences, Inc. |
Human immunoglobulin common light chain transgene constructs and uses thereof
|
|
WO2026030428A2
(en)
|
2024-08-01 |
2026-02-05 |
Regeneron Pharmaceuticals, Inc. |
Prostate-specific antigen peptides and uses thereof
|
|
US20260123608A1
(en)
|
2024-08-06 |
2026-05-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
|
|
WO2026050255A2
(en)
|
2024-08-27 |
2026-03-05 |
Regeneron Pharmaceuticals, Inc. |
Anti-slc3a2-apis antigen-binding proteins and methods of use thereof
|
|
WO2026096597A1
(en)
|
2024-10-30 |
2026-05-07 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules that bind cd22 and 4-1bb and methods of use thereof
|
|
US20260116993A1
(en)
|
2024-10-30 |
2026-04-30 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules that bind psma and 4-1bb and methods of use thereof
|
|
WO2026096736A1
(en)
|
2024-10-31 |
2026-05-07 |
Regeneron Pharmaceuticals, Inc. |
Rodents expressing humanized polymeric immunoglobulin receptor
|